Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novoic Limited
Age
50–85
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Subjects are fully eligible for and have completed the AMYPRED-US (Amyloid Prediction in early stage Alzheimer's disease from acoustic and linguistic patterns of speech) study.
(See https://clinicaltrials.gov/ct2/show/NCT04928976)
\- Subject consents to take part in FUTURE extension study.
You may not be if
Subject hasn't completed the full visit day in the AMYPRED-US study.
Clareo Health | Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension
